11.14  -0.17 (-1.5%)		04-15 16:00
Open: 11.78 High: 12.2 Volume: 32,895		Pre. Close: 11.31 Low: 10.71 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	15.87	1-year :	18.1
Resists	First :	13.59	Second :	15.5
Pivot price	11.9
Supports	First :	10.5	Second :	8.73
MAs	MA(5) :	11.12	MA(20) :	12.4
	MA(100) :	11.88	MA(250) :	58.91
MACD	MACD :	-0.7	Signal :	-0.6
%K %D	K(14,3) :	21.3	D(3) :	19.6
RSI	RSI(14): 40.5
52-week	High :	2235	Low :	2.88

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ PLRZ ] has closed above bottom band by 23.5%. Bollinger Bands are 33.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	12.21 - 12.29	12.29 - 12.36
Low:	10.57 - 10.64	10.64 - 10.7
Close:	10.75 - 10.87	10.87 - 10.97

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.

Wed, 08 Apr 2026
Polyrizon Ltd. Completes $3.5 Million Registered Direct Offering and Private Placement - Quiver Quantitative

Wed, 08 Apr 2026
Polyrizon (NASDAQ: PLRZ) prices $3.5M stock and warrant financing - Stock Titan

Wed, 08 Apr 2026
Polyrizon raises $3.5M in stock sale for working capital - Stock Titan

Wed, 08 Apr 2026
Polyrizon Ltd. (PLRZ) files $2.5M offering: 87,777 shares + 190,000 pre-funded warrants - Stock Titan

Tue, 07 Apr 2026
Single investor commits $3.5M to Polyrizon in stock-warrant deal - Stock Titan

Thu, 02 Apr 2026
PLRZ SEC Filings - Polyrizon Ltd 10-K, 10-Q, 8-K Forms - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	0 (%)
Held by Institutions	0.9 (%)
Shares Short	39 (K)
Shares Short P.Month	54 (K)

EPS	-4.91
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	18.73
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-29 %
Return on Equity (ttm)	-25.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-5.69
Qtrly Earnings Growth	0 %
Operating Cash Flow	-5 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	-2.22
PEG Ratio	0
Price to Book value	0.57
Price to Sales	0
Price to Cash Flow	-2.5

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.